Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary objective of this study is to assess the safety and tolerability of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer.
Jordan Berlin, M.D.
Ingram Professor of Cancer Research, Vanderbilt University
United States: Food and Drug Administration
|Vanderbilt-Ingram Cancer Center||Nashville, Tennessee 37232-6838|
|Sarah Cannon Research Institute||Nashville, Tennessee 37203|